株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のアレルギー性鼻炎治療薬市場:2017年〜2027年

Global Allergic Rhinitis Drugs Market 2017-2027: Oral Antihistamines, Intranasal Corticosteroids, Intranasal Antihistamines, Immunotherapy and Vaccines

発行 Visiongain Ltd 商品コード 310754
出版日 ページ情報 英文 255 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=144.90円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
世界のアレルギー性鼻炎治療薬市場:2017年〜2027年 Global Allergic Rhinitis Drugs Market 2017-2027: Oral Antihistamines, Intranasal Corticosteroids, Intranasal Antihistamines, Immunotherapy and Vaccines
出版日: 2017年05月30日 ページ情報: 英文 255 Pages
概要

世界のアレルギー性鼻炎治療薬市場は、2016年の119億米ドルから、2021年には139億米ドルまで拡大すると見られています。市場は、2016年〜2027年のCAGR (複合年間成長率) で、3.3%の成長が予測されています。

当レポートでは、世界のアレルギー性鼻炎治療薬市場について調査分析し、市場概要、セグメント別の市場分析と予測、地域別・国別の市場分析と予測、主要企業などについて、体系的な情報を提供しています。

第1章 レポート概要

第2章 アレルギー性鼻炎治療薬とは

  • 製薬業界:概要
  • アレルギーの概要
  • アレルギー性鼻炎
  • アレルギー性鼻炎の治療
  • 治験の段階
  • 調査範囲

第3章 世界のアレルギー性鼻炎治療薬市場

  • 市場概要
  • 市場の分類
  • 市場実績
  • 市場予測
  • 市場シェアの変化:部門別

第4章 経口抗ヒスタミン剤市場:市場分析と予測

  • 市場概要
  • 市場動向と発展
  • 市場予測
  • 主な経口抗ヒスタミン剤

第5章 コルチコステロイド点鼻薬市場:市場分析と予測

  • 主要製品
  • 市場予測
  • 主なコルチコステロイド点鼻薬

第6章 免疫療法とワクチン:市場分析と予測

  • 市場概要
  • 主要製品
  • 市場動向と発展
  • 市場予測
  • 種類:投与経路別
  • 主な免疫療法製品

第7章 抗ヒスタミン点鼻薬市場:市場分析と予測

  • 主要製品
  • 市場動向と発展
  • 市場予測
  • 主な抗ヒスタミン点鼻薬

第8章 主要国のアレルギー性鼻炎治療薬市場

  • アレルギー性鼻炎治療薬市場:地域別
  • 主要国市場:予測
  • 地域別のアレルギー性鼻炎治療薬市場:分析と予測
  • 中国
  • 日本
  • ロシア
  • インド
  • ブラジル
  • その他

第9章 アレルギー性鼻炎治療薬市場の主要企業

  • アレルギー性鼻炎治療薬:進化する市場空間
  • ALK-Abello
  • GlaxoSmithKline (GSK)
  • Johnson & Johnson
  • 協和発酵キリン
  • Merck & Co.
  • Sanofi
  • Stallergenes Greer
  • UCB
  • その他

第10章 アレルギー性鼻炎治療薬:研究開発パイプライン

  • 動向と発展
  • 経口抗ヒスタミン剤
  • コルチコステロイド点鼻薬
  • 免疫療法
  • その他

第11章 アレルギー性鼻炎治療薬市場の定性分析

  • 影響を与える市場要因
  • SWOT分析
  • ファイブフォース分析

第12章 結論

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0196

The global allergic rhinitis drugs market is expected to grow at a CAGR of 3.2% in the first half of the forecast period. The market is expected to grow at a CAGR of 3.3% from 2016-2027. The market is estimated at $11.9bn in 2016 and $13.9bn in 2021.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 255-page report you will receive 85 tables and 88 figures - all unavailable elsewhere.

The 255-page report provides clear detailed insight into the global allergic rhinitis drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Global Allergic Rhinitis Drugs Market forecasts from 2017-2027
  • Along with revenue prediction for the overall world market for allergic rhinitis drugs, our investigation shows forecasts to 2027 for the following submarkets:
    • Intranasal Antihistamines
    • Intranasal Corticosteroids
    • Oral Antihistamines
    • Immunotherapy and Vaccines
  • How will leading allergic rhinitis drugs perform to 2027 at world level? Our study forecasts individual revenues of these 27 products:
    • Patanase
    • Astepro
    • Astelin
    • Dymista
    • Nasonex
    • Avamys
    • Veramyst
    • Flixonase
    • Rhinocort
    • Omnaris
    • Nasacort
    • Beconase
    • Qnasl
    • Zetonna
    • Allegra
    • Zyrtec
    • Claritin
    • Xyzal
    • Allelock
    • Clarinex
    • Ebastel
    • Talion
    • Staloral
    • Alutard SQ
    • Grazax
    • Ragwitek
    • Generic Azelastine
  • This report provides individual revenue forecasts to 2027 for these regional and national markets:
    • US
    • EU5
    • Germany, UK, France, Italy and Spain
    • China
    • Japan
    • India
    • Russia
    • Brazil
    • Rest of the World
  • Our work provides analysis and sales forecast of the leading companies in the allergic rhinitis drugs market:
    • GlaxoSmithKline (GSK)
    • Merck & Co
    • Sanofi
    • Johnson & Johnson
    • ALK-Abello
    • UCB
    • Kyowo Hako Kirin
    • Stallergenes Greer
  • This report discusses the trends and development in the allergic rhinitis pipeline
  • Our study discusses strengths, weaknesses, opportunities and threats as well as porter's five forces analysis of the global allergic rhinitis drugs market

Visiongain's study is intended for anyone requiring commercial analyses for the global allergic rhinitis drugs market. You find data, trends and predictions.

Buy our report today Global Allergic Rhinitis Drugs Market 2017-2027: Oral Antihistamines, Intranasal Corticosteroids, Intranasal Antihistamines, Immunotherapy and Vaccines.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Allergic Rhinitis Drugs: Market Overview
  • 1.2. Global Allergic Rhinitis Drugs Market Segmentation
  • 1.3. Overview of Findings
  • 1.4. Structure of the Report
  • 1.5. Why You Should Read This Report
  • 1.6. How This Report Delivers
  • 1.7. Key Questions Answered by This Analytical Report
  • 1.8. Who is This Report For?
  • 1.9. Methodology
  • 1.10. Frequently Asked Questions (FAQ)
  • 1.11. Associated Visiongain Reports
  • 1.12. About Visiongain

2. An Introduction to Allergic Rhinitis Drugs

  • 2.1. The Pharmaceutical Industry: A Brief Introduction
    • 2.1.1. Allergic Rhinitis Treatments-An Industry Overview
  • 2.2. A Brief Overview of Allergy
  • 2.3. Allergic Rhinitis
    • 2.3.1. The Global Prevalence of Allergic Rhinitis
    • 2.3.2. Pathophysiology of Allergic Rhinitis: IgEs and Mast Cells
    • 2.3.3. Symptoms of Allergic Rhinitis
    • 2.3.4. Classification of Allergic Rhinitis
  • 2.3.4.1. Non-Allergic Rhinitis and Mixed Rhinitis
    • 2.3.5. Seasonal Allergic Rhinitis (Hay Fever)
    • 2.3.6. Perennial Allergic Rhinitis
    • 2.3.7. Diagnosis of Allergic Rhinitis
  • 2.4. Treatment of Allergic Rhinitis
    • 2.4.1. Antihistamines
      • 2.4.1.1. First-Generation Antihistamines
      • 2.4.1.2. Second- and Third-Generation Antihistamines
    • 2.4.2. Corticosteroids
      • 2.4.2.1. First-, Second- and Third-Generation Intranasal Corticosteroids
      • 2.4.2.2. Combination Drug Products
    • 2.4.3. Leukotriene Receptor Antagonists
    • 2.4.4. Cromolyn (cromoglicic acid)
    • 2.4.5. Decongestants
    • 2.4.6. Saline Nasal Sprays
    • 2.4.7. Immunotherapy and Vaccines
  • 2.5. Phases of Clinical Trials
  • 2.6. Scope of this Report

3. The Global Allergic Rhinitis Drugs Market, 2017-2027

  • 3.1. The Global Allergic Rhinitis Drugs Market: Market Overview
  • 3.2. Categorisation of The Global Allergic Rhinitis Drugs Market
  • 3.3. The Global Allergic Rhinitis Drugs Market in 2016
  • 3.4. The Global Allergic Rhinitis Drugs Market: Market Forecast 2017-2027
  • 3.5. Allergic Rhinitis Drugs: Changing Market Shares by Sector 2017-2027

4. Oral Antihistamines Market: Market Analysis and Forecast 2017-2027

  • 4.1. Oral Antihistamines: Market Overview
    • 4.1.1. Leading Products in the Oral Antihistamines Market, 2016
  • 4.2. Oral Antihistamines: Market Trends and Developments, 2017
    • 4.2.1. Patent Expiries and the Threat of Generics
    • 4.2.2. The Increasing Switch from Prescription to Over-The-Counter Sales
    • 4.2.3. The Potential for Combination Therapy with Intranasal Corticosteroids
  • 4.3. Oral Antihistamines: Market Forecast 2017-2027
    • 4.3.1. Oral Antihistamines: Changing Market Shares by Leading Drugs 2017-2027
  • 4.4. Leading Oral Antihistamines for the Treatment of Allergic Rhinitis
    • 4.4.1. Allegra/Allegra-D/Allegra OTC (fexofenadine) - Sanofi
      • 4.4.1.1. Allegra/Allegra OTC: Historical Sales, 1995-2014
      • 4.4.1.2. Allegra/Allegra OTC: Sales Forecast 2016-2027
    • 4.4.2. Claritin/Claritin OTC (loratadine)-Bayer/ Merck & Co
      • 4.4.2.1. Claritin/Claritin OTC: Sales Forecast 2017-2027
    • 4.4.3. Zyrtec/Zyrtec D (cetirizine) - Johnson & Johnson/ UCB/ GSK
      • 4.4.3.1. Zyrtec/Zyrtec D: Sales Forecast 2017-2027
    • 4.4.4. Xyzal (levocetirizine) - Sanofi/ UCB/ GSK
      • 4.4.4.1. Xyzal: Sales Forecast 2017-2027
    • 4.4.5. Clarinex (desloratadine) - Merck & Co.
      • 4.4.5.1. Clarinex: Sales Forecast 2017-2027
    • 4.4.6. Allelock (olopatadine) - Kyowa Hakko Kirin
      • 4.4.6.1. Allelock: Sales Forecast 2017-2027
    • 4.4.7. Ebastel (ebastine) - AstraZeneca/Takeda/Dainippon Sumitomo
      • 4.4.7.1. Ebastel: Sales Forecast 2017-2027
    • 4.4.8. Talion (bepotastine) - Mitsubishi Tanabe
      • 4.4.8.1. Talion: Sales Forecast 2017-2027
    • 4.4.9. Other Oral Antihistamines: Sales Forecast 2017-2027

5. Intranasal Corticosteroids Market: Market Analysis and Forecast 2017-2027

  • 5.1. Leading Products in the Intranasal Corticosteroids Market, 2016
  • 5.2. Intranasal Corticosteroids: Market Forecast 2017-2027
    • 5.2.1. Intranasal Corticosteroids: Changing Market Shares by Leading Drugs 2017-2027
  • 5.3. Leading Intranasal Corticosteroids
    • 5.3.1. Flixonase/Flonase/Flonase-OTC (fluticasone propionate) - GlaxoSmithKline
      • 5.3.1.1. Flixonase/Flonase/Flonase-OTC Forecast, 2017-2027
    • 5.3.2. Nasonex (mometasone) - Merck
      • 5.3.2.1. Nasonex Forecast, 2017-2027
    • 5.3.3. Avamys/Veramyst (fluticasone furoate) - GlaxoSmithKline
      • 5.3.3.1. Avamys/Veramyst Forecast, 2017-2027
    • 5.3.4. Rhinocort (budesonide) - AstraZeneca
      • 5.3.4.1. Rhinocort Forecast, 2017-2027
    • 5.3.5. Nasacort/Nasacort-OTC (triamcinolone) - Sanofi
      • 5.3.5.1. Nasacort/Nasacort-OTC Forecast, 2017-2027
    • 5.3.6. Omnaris (ciclesonide) - Dainippon Sumitomo/Takeda
      • 5.3.6.1. Omnaris: Sales Forecast, 2017-2027
    • 5.3.7. Beconase/Beconase AQ (beclometasone) - GlaxoSmithKline/Omega Pharma
      • 5.3.7.1. Beconase/Beconase AQ Forecast, 2017-2027
    • 5.3.8. Qnasl (beclometasone) - Teva
      • 5.3.8.1. Qnas Forecast, 2017-2027
    • 5.3.9. Zetonna (ciclesonide) - Dainippon Sumitomo
      • 5.3.9.1. Zetonna Forecast, 2017-2027

6. Immunotherapy and Vaccines: Market Analysis and Forecast 2017-2027

  • 6.1. Immunotherapy and Vaccines: Market Overview
    • 6.1.1. Immunotherapy: Primed for Rapid Expansion
  • 6.2. Leading Immunotherapy Products in the Allergic Rhinitis Market, 2016
  • 6.3. Allergic Rhinitis Immunotherapy: Market Trends and Developments, 2016
    • 6.3.1. Subcutaneous and Sublingual Immunotherapy
    • 6.3.2. Expansion into the US Market
    • 6.3.3. Standardisation of Immunotherapy Products
    • 6.3.4. Immunotherapy as a Preventative Treatment
  • 6.4. Allergic Rhinitis Immunotherapy: Market Forecast 2017-2027
    • 6.4.1. Allergic Rhinitis Immunotherapy: Changing Market Shares by Leading Products 2017-2027
  • 6.5. Immunotherapy Type-By Route of Administration, 2016
  • 6.6. Leading Immunotherapy Products for Allergic Rhinitis
    • 6.6.1. Staloral (Grass pollen allergen extract) - Stallergenes
      • 6.6.1.1. Staloral: Sales Forecast 2017-2027
    • 6.6.2. Alutard SQ (Grass pollen allergen extract) - ALK-Abelló
      • 6.6.2.1. Alutard SQ: Sales Forecast 2017-2027
    • 6.6.3. Grazax/Grastek (Timothy grass pollen allergen extract) - ALK-Abelló/Merck
      • 6.6.3.1. Grazax/Grastek: Sales Forecast 2016-2027
    • 6.6.4. Oralair (Grass pollen allergen extract) - Stallergenes/Greer
      • 6.6.4.1. Oralair: Sales Forecast 2017-2027
    • 6.6.5. Ragwitek (Short ragweed pollen allergen extract) - Merck
      • 6.6.5.1. Ragwitek: Sales Forecast 2017-2027
    • 6.6.6. Other Allergic Rhinitis Immunotherapy Products: Sales Forecast 2017-2027

7. The Intranasal Antihistamines Market: Market Analysis and Forecast 2017-2027

  • 7.1. Leading Products in the Intranasal Antihistamines Market, 2016
  • 7.2. Intranasal Antihistamines: Market Trends and Developments, 2017
    • 7.2.1. Azelastine versus Olopatadine
  • 7.2.2. Intranasal Combination Products
  • 7.3. Intranasal Antihistamines: Market Forecast 2017-2027
    • 7.3.1. Intranasal Antihistamines: Changing Market Shares by Leading Drugs 2017-2027
  • 7.4. Leading Intranasal Antihistamines
    • 7.4.1. Dymista (azelastine/fluticasone) - Meda Pharmaceuticals
      • 7.4.1.1. Mylan Acquires Meda Pharmaceuticals
      • 7.4.1.2. Dymista: Sales Forecast 2017-2027
    • 7.4.2. Generic Intranasal Azelastine
      • 7.4.2.1. Generic Intranasal Azelastine: Sales Forecast, 2017-2027
    • 7.4.3. Astepro (azelastine)-Meda Pharmaceuticals
      • 7.4.3.1. Astepro: Sales Forecast 2016-2027
    • 7.4.4. Patanase (olopatadine) - Novartis
      • 7.4.4.1. Patanase: Sales Forecast 2016-2027
    • 7.4.5. Astelin (azelastine) - Meda Pharmaceuticals
      • 7.4.5.1. Astelin: Sales Forecast 2017-2027

8. Leading National Markets for Allergic Rhinitis Drugs, 2016-2027

  • 8.1. The Allergic Rhinitis Drugs Market by Region
    • 8.1.1. The Global Distribution of Allergic Rhinitis Drugs in 2016
  • 8.2. Leading National Markets: Forecast 2016-2027
    • 8.2.1. Changing Market Shares by Region, 2016-2027
  • 8.3. Regional Allergic Rhinitis Drugs Markets: Analysis and Forecasts, 2016-2027
    • 8.3.1. United States: The Largest Allergic Rhinitis Drugs Market
      • 8.3.1.1. US Allergic Rhinitis Drugs Market: Trends and Developments
      • 8.3.1.2. US Allergic Rhinitis Drugs Market: Market Forecast 2016-2027
    • 8.3.2. EU5
      • 8.3.2.1. EU5. Allergic Rhinitis Drugs Market: Market Forecast 2016-2027
      • 8.3.2.2. EU5. Markets: Changing Market Shares by Country, 2016-2027
      • 8.3.2.3. Germany
      • 8.3.2.4. UK
      • 8.3.2.5. France
      • 8.3.2.6. Italy
      • 8.3.2.7. Spain
  • 8.4. China
    • 8.4.1. Air Pollution Associated with Increasing Prevalence
    • 8.4.2. Expansion of Healthcare Coverage and Reimbursement in China
    • 8.4.3. China Allergic Rhinitis Drugs Market: Market Forecast 2016-2027
  • 8.5. Japan
    • 8.5.1. Cedar Reforestation and the Hay Fever Epidemic
    • 8.5.2. Genetically Modified Rice as Immunotherapy
    • 8.5.3. Effects of the Rising Levels of Generic Drug Penetration
    • 8.5.4. Japan Allergic Rhinitis Drugs Market: Market Forecast 2016-2027
  • 8.6. Russia
    • 8.6.1. How Will Russia's Economic Status Affect Its Pharma Industry?
    • 8.6.2. Russia Allergic Rhinitis Drugs Market: Market Forecast 2016-2027
  • 8.7. India
    • 8.7.1. The Impact of the Drug Prices Control Order on Indian Pharma
    • 8.7.2. India's Expansion of Healthcare Provision
    • 8.7.3. India Allergic Rhinitis Drugs Market: Market Forecast 2016-2027
  • 8.8. Brazil
    • 8.8.1. How Will Brazil's Growing Healthcare Influence Allergic Rhinitis Drugs
    • 8.8.2. Brazil Allergic Rhinitis Drugs Market: Market Forecast 2016-2027
  • 8.9. Rest of the World
    • 8.9.1. Rest of the World Allergic Rhinitis Drugs Market: Market Forecast 2016-2027

9. Leading Companies in the Allergic Rhinitis Drugs Market, 2016-2027

  • 9.1. Allergic Rhinitis Drugs-An Evolving Market Space
    • 9.1.1. Leading Companies in the Allergic Rhinitis Drugs Market, 2016
  • 9.2. ALK-Abelló
    • 9.2.1. ALK-Abelló: Allergic Rhinitis Drugs Portfolio, 2017
    • 9.2.2. ALK-Abelló: Recent Developments
      • 9.2.2.1. ALK Acquired Allergy Laboratories, Inc. and Crystal Laboratory LLC to Strengthen Its Supply Chain Activities
      • 9.2.2.2. ACARIZAX Launched in Europe progressing to International Roll-Out
      • 9.2.2.3. ALK Collaborates with EddingPharm to Boost China Sales
      • 9.2.2.4. ALK-Abelló: Sales Forecast 2016-2027
      • 9.2.2.5. ALK-Abelló: Allergic Rhinitis Drug Development Pipeline, 2016
  • 9.3. GlaxoSmithKline (GSK)
    • 9.3.1. GlaxoSmithKline: Allergic Rhinitis Drugs Portfolio, 2017
    • 9.3.2. GlaxoSmithKline: Sales Forecast 2016-2027
  • 9.4. Johnson & Johnson
    • 9.4.1. Johnson & Johnson: Allergic Rhinitis Drugs Portfolio, 2017
    • 9.4.2. Johnson & Johnson: Recent Developments
      • 9.4.2.1. Manufacturing Recalls at McNeil Consumer Healthcare
      • 9.4.2.2. Johnson & Johnson: Sales Forecast 2016-2027
  • 9.5. Kyowa Hakko Kirin
    • 9.5.1. Kyowa Hakko Kirin: Allergic Rhinitis Drugs Portfolio, 2017
    • 9.5.2. Kyowa Hakko Kirin: Sales Forecast 2016-2027
  • 9.6. Merck & Co.
    • 9.6.1. Merck: Allergic Rhinitis Drugs Portfolio, 2017
    • 9.6.2. Merck: Recent Developments
      • 9.6.2.1. Bayer Acquires Merck's Consumer Health Business
      • 9.6.2.2. FDA Rejects Singulair OTC Switch
      • 9.2.6.3. Merck: Sales Forecast 2016-2027
      • 9.2.6.4. Merck: Allergic Rhinitis Drug Development Pipeline, 2017
  • 9.7. Sanofi
    • 9.7.1. Sanofi: Allergic Rhinitis Drugs Portfolio, 2017
    • 9.7.2. Sanofi: Sales Forecast 2016-2027
    • 9.7.3. Sanofi: Recent Developments
      • 9.7.3.1. Sanofi Received US FDA Approval for Its Xyzal Allergy 24HR
  • 9.8. Stallergenes Greer
    • 9.8.1. Stallergenes: Allergic Rhinitis Drugs portfolio, 2017
    • 9.8.2. Stallergenes Greer: Sales Forecast 2016-2027
    • 9.8.3. Stallergenes Greer: Allergic Rhinitis Drug Development Pipeline, 2017
  • 9.9. UCB
    • 9.9.1. UCB: Allergic Rhinitis Drugs Portfolio, 2017
    • 9.9.2. UCB: Sales Forecast 2016-2027
  • 9.10. Other Leading Companies within the Allergic Rhinitis Drugs Market

10. Allergic Rhinitis Drugs: Research and Development Pipeline, 2016-2027

  • 10.1. Trends and Developments in the Allergic Rhinitis Pipeline
  • 10.2. The R&D Pipeline for Oral Antihistamines, 2017
    • 10.2.1. Talion (bepotastine) - Mitsubishi Tanabe
    • 10.2.2. ZPL-3893787(histamine H4R antagonist) - Ziarco Pharma
  • 10.3. The R&D Pipeline for Intranasal Corticosteroids, 2017
    • 10.3.1. APC-3000(HFA inhaled corticosteroid) - Adamis Pharmaceuticals
    • 10.3.2. TBS-6 - Trimel Pharmaceuticals
  • 10.4. The R&D Pipeline for Immunotherapy in Allergic Rhinitis, 2017
    • 10.4.1. Actair (house dust mite SLIT; STG320) - Stallergenes/Shionogi & Co
    • 10.4.2. AllerT (subcutaneous birch pollen immunotherapy) - Anergis
    • 10.4.3. Depigoid Birch 5000(birch pollen allergen extract, Leti Pharma
    • 10.4.4. House Dust Mite SLIT-Tablet (MK-8237) - ALK-Abelló/Merck/Torii
    • 10.4.5. Pollinex Quattro (subcutaneous immunotherapies) - Allergy Therapeutics
    • 10.4.6. gp-ASIT+ (grass pollen allergen fragments) - Biotech Tools
    • 10.4.7. Betula verrucosa (Bet v) 1 allergen-Stallergenes Greer
  • 10.5. The R&D Pipeline for Other Allergic Rhinitis Drugs
    • 10.5.1. S-555739 (prostaglandin D2 receptor antagonist) - Shionogi
    • 10.5.2. DSP-3025/AZD-8848 (toll-like receptor 7 agonist) - Dainippon Sumitomo/ AstraZeneca
    • 10.5.3. GSK2245035 (toll-like receptor 7 agonist) - GSK
    • 10.5.4. HP-3060 (transdermal long-acting tape) - Hisamitsu
    • 10.5.5. MRX-4 (anti-inflammatory agent) - Celsus Therapeutics

11. Qualitative Analysis of the Allergic Rhinitis Drugs Market, 2016-2027

  • 11.1. Market Factors Influencing Allergic Rhinitis Drugs
  • 11.2. SWOT Analysis of The Global Allergic Rhinitis Drugs Market, 2016-2027
    • 11.2.1. Strengths
      • 11.2.1.1. OTC-Switch Facilitating Ease of Consumer Access
      • 11.2.1.2. The Established Role of Allergic Rhinitis Drugs in Treatment
      • 11.2.1.3. Allergic Rhinitis and Rising Unmet Clinical Need
      • 11.2.1.4. Rising Profile of Allergic Rhinitis in Various Regions Driving Healthcare Provision
    • 11.2.2. Weaknesses
      • 11.2.2.1. Intranasal Corticosteroids and Patients' Satisfaction Rates
      • 11.2.2.2. Increasing Penetration of Generic Drug Products
      • 11.2.2.3. The Challenge Raised by The Low Volume of Pipeline Developments
    • 11.2.3. Opportunities
      • 11.2.3.1. Growth in Emerging Markets Outstripping Established Markets
      • 11.2.3.2. Rx-to-OTC Switching and The Effects on Revenue Potential
      • 11.2.3.3. Combination Drug Products Providing Rising Efficacy Profiles
      • 11.2.3.4. The Emergence of Immunotherapy in Allergic Rhinitis
    • 11.2.4. Threats
      • 11.2.4.1. Cost-Containment as A Growth Restraint
      • 11.2.4.2. Rising Cost of APIs and Manufacturing
      • 11.2.4.3. Patent Expiries and The Resultant Loss of Revenue
  • 11.3. Porter's Five Forces Analysis of the Global Allergic Rhinitis Drugs Market, 2016-2027
    • 11.3.1. Power of Buyers
    • 11.3.2. Power of Suppliers
    • 11.3.3. Threat of Substitutes
    • 11.3.4. Threat 0f New Entrants
    • 11.3.5. Rivalry Among Competitors

12. Conclusion

  • 12.1. Overview of Current Market Conditions and Market Forecast, 2016-2027
  • 12.2. Leading Sectors in the Allergic Rhinitis Drugs Market in 2016
  • 12.3. Leading Regions in the Allergic Rhinitis Drugs Market in 2016
  • 12.4. Leading Companies in the Allergic Rhinitis Drugs Market, 2016
  • 12.5. What Does the Future Hold for Allergic Rhinitis Drugs?

Associated Reports

  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 1.1: (Sample) Allergic Rhinitis Market Forecast by National Market: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 2.1: Leading Antihistamines for Allergic Rhinitis, 2017
  • Table 2.2: Leading Corticosteroids for Allergic Rhinitis, 2017
  • Table 2.3: Clinical Trial Phases
  • Table 3.1: The Global Allergic Rhinitis Drugs Market: Revenue ($m) and Market Shares (%) by Sector, 2016
  • Table 3.2: The Global Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 3.3: The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2016, 2021, 2027
  • Table 4.1: Leading Oral Antihistamines: Revenue ($m) and Market Share (%), 2016
  • Table 4.2: Oral Antihistamines Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.3: The Global Oral Antihistamines Market: Market Share (%), 2016, 2021, 2027
  • Table 4.4: Allegra/Allegra-D/Allegra OTC Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.5: Claritin/Claritin OTC Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.6: Zyrtec/Zyrtec-D Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.7: Xyzal Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.8: Clarinex Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.9: Allelock Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.10: Ebastel Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.11: Talion Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.12: Other Oral Antihistamines Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
  • Table 5.1: Leading Drugs In The Intranasal Corticosteroids Market: Revenue ($m) and Market Shares (%), 2016
  • Table 5.2: Intranasal Corticosteroids Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.3: The Global Intranasal Corticosteroids Market: Market Share (%), 2016, 2021, 2027
  • Table 5.4: Flixonase/Flonase/Flonase-OTC Forecast: Revenue ($m), AGR (%), and CAGR (%), 2016-2027
  • Table 5.5: Nasonex Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 5.6: Avamys/Veramyst Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 5.7: Rhinocort: Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 5.8: Nasacort/Nasacort-OTC Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 5.9: Omnaris Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 5.10: Beconase/Beconase AQ Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 5.11: Qnasl Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 5.12: Zetonna Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.1: Leading Allergic Rhinitis Immunotherapy Products: Revenue ($m) and Market Share (%), 2016
  • Table 6.2: Allergic Rhinitis Immunotherapy Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.3: The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2016, 2021, 2027
  • Table 6.4: Allergic Rhinitis Immunotherapy Market by Type: Revenue ($m) and Market Share (%), 2016
  • Table 6.5: Staloral Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.6: Alutard SQ Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.7: Grazax/Grastek Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.8: Oralair Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.9: Ragwitek Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.10: Other Allergic Rhinitis Immunotherapy Products Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 7.1: Top Drugs In The Intranasal Antihistamines Market: Revenue ($m) and Market Shares (%), 2016
  • Table 7.2: Intranasal Antihistamines Market Forecast by Leading Drugs: Revenue ($m), AGR (%), and CAGR%), 2016-2027
  • Table 7.3: The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%), 2016, 2021, 2027
  • Table 7.4: Dymista (Meda Pharma) Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 7.5: Generic Intranasal Azelastine Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 7.6: Astepro Forecast; Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 7.7: Patanase Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 7.8: Astelin Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 8.1: The Global Allergic Rhinitis Drugs Market by Region: Revenue ($m) and Market Share (%), 2016
  • Table 8.2: Global Allergic Rhinitis Drugs Market Forecast by Region: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 8.3: The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2016, 2021, and 2027
  • Table 8.4: US Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 8.5: The EU5 Allergic Rhinitis Drugs Market Forecast by Country: Revenue ($m) and Market Share (%), 2016
  • Table 8.6: The EU5 Allergic Rhinitis Drugs Market Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
  • Table 8.7: The EU5 Allergic Rhinitis Drugs Market by Country: Market Share (%), 2016, 2021, 2027
  • Table 8.8: Germany Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 8.9: UK Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 8.10: France Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%), and CAGR (%), 2016-2027
  • Table 8.11: Italy Allergic Rhinitis Drugs Market Forecat: Revenue ($m), AGR (%), and CAGR (%), 2016-2027
  • Table 8.12: Spain Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%), and CAGR (%), 2016-2027
  • Table 8.13: China Allergic Rhinitis Drugs Market Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
  • Table 8.14: Japan Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%), and CAGR (%), 2016-2027
  • Table 8.15: Russia Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 8.16: India Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 8.17: Brazil Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 8.18: Rest of the World Allergic Rhinitis Drugs Market Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
  • Table 9.1: Leading Companies in The Allergic Rhinitis Drug Market: Revenues ($m) and Market Shares (%), 2016
  • Table 9.2: ALK- Abelló: Company Overview, 2017
  • Table 9.3: ALK-Abelló: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 9.4: GlaxoSmithKline: Company Overview, 2017
  • Table 9.5: GlaxoSmithKline: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 9.6: Johnson & Johnson: Company Overview, 2017
  • Table 9.7: Johnson & Johnson Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 9.8: Kyowa Hakko Kirin: Company Overview, 2017
  • Table 9.9: Kyowa Hakko Kirin: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 9.10: Merck & Co.: Company Overview, 2017
  • Table 9.11: Merck & Co: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 9.12: Sanofi: Company Overview, 2017
  • Table 9.13: Sanofi: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 9.14: Stallergenes Greer: Company Overview, 2016
  • Table 9.15: Stallergenes Greer: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 9.16: UCB: Company Overview, 2017
  • Table 9.17: UCB: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 11.1: SWOT Analysis of the Global Allergic Rhinitis Drugs Market, 2016-2027

List of Figures

  • Figure 1.1: Global Allergic Rhinitis Drugs Market: Market Sectors, 2017
  • Figure 2.1: Role of Mast Cells and IgE in Allergic Rhinitis, 2017
  • Figure 3.1: The Global Allergic Rhinitis Drugs Market: Revenue ($m) by Sector, 2016
  • Figure 3.2: The Global Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%) by Sector, 2016-2027
  • Figure 3.3: The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2016
  • Figure 3.4: The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2021
  • Figure 3.5: The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2027
  • Figure 4.1: Leading Oral Antihistamines: Revenue ($m), 2016
  • Figure 4.2: Oral Antihistamines Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 4.3: The Global Oral Antihistamines Market: Market Share (%), 2016
  • Figure 4.4: The Global Oral Antihistamines Market: Market Share (%), 2021
  • Figure 4.5: The Global Oral Antihistamines Market: Market Share (%), 2027
  • Figure 4.6: Allegra (Allegra Rx and Allegra OTC) Historical Sales: Revenue ($m),1995-2016
  • Figure 4.7: Allegra/Allegra-D/Allegra OTC Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 4.8: Claritin/Claritin OTC Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 4.9: Zyrtec/Zyrtec-D Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 4.10: Xyzal Forecast: Revenue($m) and AGR (%), 2016-2027
  • Figure 4.11: Clarinex Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 4.12: Allelock Forecast: Revenue($m) and AGR (%), 2016-2027
  • Figure 4.13: Ebastel Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 4.14: Talion Forecast: Revenue($m) and AGR (%), 2016-2027
  • Figure 4.15: Other Oral Antihistamines Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 5.1: Leading Drugs In The Intranasal Corticosteroids Market: Revenue ($m), 2016
  • Figure 5.2: Intranasal Corticosteroids Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 5.3: The Global Intranasal Corticosteroids Market by Leading Drugs: Market Share (%), 2016
  • Figure 5.4: The Global Intranasal Corticosteroids Market by Leading Drugs: Market Share (%), 2021
  • Figure 5.5: The Global Intranasal Corticosteroids Market by Leading Drugs: Market Share (%), 2027
  • Figure 5.6: Flixonase/Flonase/Flonase-OTC Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 5.7: Nasonex Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 5.8: Avamys/Veramyst Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 5.9: Rhinocort Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 5.10: Nasacort/Nasacort-OTC Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 5.11: Omnaris Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 5.12: Beconase/Beconase AQ Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 5.13: Qnasl Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 5.14: Zetonna Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 6.1: Leading Allergic Rhinitis Immunotherapy Products: Revenue ($m), 2016
  • Figure 6.2: Allergic Rhinitis Immunotherapy Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 6.3: The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2016
  • Figure 6.4: The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2021
  • Figure 6.5: The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2027
  • Figure 6.6: Allergic Rhinitis Immunotherapy Market: Market Share (%) by Immunotherapy Type, 2016
  • Figure 6.7: Staloral Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 6.8: Alutard SQ Forecast: Revenue($m) and AGR (%), 2016-2027
  • Figure 6.9: Grazax/Grastek Forecast: Revenue($m) and AGR (%), 2016-2027
  • Figure 6.10: Oralair Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 6.11: Ragwitek Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 6.12: Other Allergic Rhinitis Immunotherapy Products Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 7.1: Top Drugs in The Intranasal Antihistamines Market: Revenue ($m), 2016
  • Figure 7.2: Intranasal Antihistamines Market Forecast: Revenue ($m), AGR (%), 2016-2027
  • Figure 7.3: The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%), 2016
  • Figure 7.4: The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%), 2021
  • Figure 7.5: The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%), 2027
  • Figure 7.6: Dymista (Meda Pharma) Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 7.7: Generic Intranasal Azelastine Forecast: Revenue ($m) and, AGR (%), 2016-2027
  • Figure 7.8: Astepro Forecast: Revenue ($m), and AGR (%), 2016-2027
  • Figure 7.9: Patanase Forecast: Revenue($m) and AGR (%), 2016-2027
  • Figure 7.10: Astelin Forecast: Revenue ($m), AGR (%), 2016-2027
  • Figure 8.1: The Global Allergic Rhinitis Drugs Market by Region: Revenue ($m), 2016
  • Figure 8.2: The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2016
  • Figure 8.3: The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2021
  • Figure 8.4: The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2027
  • Figure 8.5: US Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 8.6: The EU5 Allergic Rhinitis Drugs Market by Country: Revenue ($m), 2016
  • Figure 8.7: The EU5 Allergic Rhinitis Drugs Market: Market Share (%), 2016
  • Figure 8.8: The EU5 Allergic Rhinitis Drugs Market: Market Share (%), 2021
  • Figure 8.9: The EU5 Allergic Rhinitis Drugs Market: Market Share (%), 2027
  • Figure 8.10: Germany Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 8.11: UK Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 8.12: France Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 8.13: Italy Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 8.14: Spain Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 8.15: China Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 8.16: Japan Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 8.17: Russia Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 8.18: India Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 8.19: Brazil Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 8.20: Rest of the World Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 9.1: Leading Companies in The Allergic Rhinitis Drug Market: Revenues ($m), 2016
  • Figure 9.2: ALK-Abelló: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%), 2016-2027
  • Figure 9.3: GlaxoSmithKline Allergic Rhinitis Drugs Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 9.4: Johnson & Johnson Allergic Rhinitis Drugs Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 9.5: Kyowa Hakko Kirin: Allergic Rhinitis Drugs Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 9.6: Merck & Co: Allergic Rhinitis Drugs Revenue Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 9.7: Sanofi: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2016-2027
  • Figure 9.8: Stallergenes Greer: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2016-2027
  • Figure 9.9: UCB: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2016-2027
  • Figure 11.1: Porter's Five Forces Analysis of the Allergic Rhinitis Drugs Market, 2017

Companies Listed

  • ActoGeniX
  • Adamis Pharmaceuticals
  • ALK- Abelló
  • Allergy Medical UK
  • Allergy Therapeutics
  • Almirall
  • Altana Pharma (Nycomed)
  • Anergis
  • Apotex
  • AstraZeneca
  • Atopix Therapeutics
  • Barr Laboratories
  • Bausch & Lomb
  • Belcher Pharmaceuticals
  • Biotech Tools
  • Catalent Pharma Solutions
  • Celsus Therapeutics
  • Dainippon Sumitomo
  • DBV Technologies
  • Dr Reddy's Laboratories
  • Eddingpharm
  • Eleventa
  • Genzyme (Sanofi)
  • GlaxoSmithKline
  • Greer Laboratories
  • Hisamitsu Pharmaceutical Co
  • Hoechst AG
  • Human Genome Sciences
  • Intas Pharmaceuticals
  • Johnson & Johnson
  • Keldman Healthcare
  • Kyowa Hakko Kirin
  • Leti Pharma (Laboratorios Leti)
  • Lupin Pharmaceuticals
  • Meda Pharma
  • Medpointe Inc (Meda Pharma)
  • Merck & Co
  • Mitsubishi Tanabe Pharma
  • Mylan
  • Nippon Paper Group
  • Novartis
  • Omega Pharma
  • Perrigo
  • Pfizer
  • ProStrakan (Kyowa Hakko Kirin)
  • Reckitt Benckiser
  • Roxane Laboratories (Boehringer Ingelheim)
  • Sanofi
  • Schering-Plough (Merck)
  • Shionogi & Co Ltd
  • Stallergenes
  • Sun Pharmaceuticals
  • Sunovion Pharmaceuticals (Dainippon Sumitomo)
  • Takeda
  • Teva Pharmaceuticals
  • Trimel Pharmaceuticals
  • Ube Industries
  • UCB
  • ViiV Healthcare
  • Wockhardt
  • Ziarco Pharma

Organizations Mentioned in the Report

  • Allergy & Asthma Network
  • AllergyUK
  • American Academy of Allergy, Asthma and Immunology (AAAAI)
  • British Society for Allergy & Clinical Immunology (BSACI) [UK]
  • Farmácia Popular [Brazil]
  • Imperial College London
  • International Nurses Group In Immunodeficiencies
  • Japanese Ministry of Health, Labour and Welfare
  • Les Entreprises Du Médicament (Leem) [France]
  • National Development and Reform Commission (NDRC) [China]
  • National Pharmaceutical Pricing Authority (NPPA) [India]
  • PollenUK
  • The Pharmaceutical Research and Manufacturers of America (PhRMA)
  • The UK Health and Social Care Information Centre
  • Université Libre de Bruxelles [Belgium]
  • University of Leuven [Belgium]
  • US Attorney's Office for the Eastern District of Pennsylvania
  • US Food and Drug Administration (FDA)
  • World Allergy Organisation
  • World Health Organisation (WHO)
Back to Top